GlassScriptPhysician profile
Damon Van Mauldin
NPI 1427166933
$1,382.67
in general payments reported to CMS, 2019-2025
11 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.98 · 2020: $36.29 · 2022: $249 · 2023: $496 · 2024: $321 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $551.06 | 2023-2025 | Zoryve |
| Abbvie INC. | $379.82 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $213.97 | 2019-2025 | |
| Genzyme Corporation | $56.34 | 2024 | |
| Pfizer INC. | $48.18 | 2022-2024 | |
| Janssen Biotech, INC. | $40.43 | 2019-2020 | |
| Galderma Laboratories, L.P. | $30.08 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.12 | 2025 | Cabtreo, Siliq, Jublia |
| Lilly USA, LLC | $13.98 | 2024 | Taltz, Ebglyss |
| Phadia US INC. | $13.18 | 2023 | Immunocap |
| Incyte Corporation | $12.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Mauldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.